About Us

Photo of Mark A. McIntoshMU Vice Chancellor for Research and Economic Development

Dr. Mark A. McIntosh

Dr. McIntosh has many years of experience with research development and university administration at the departmental, college and institutional levels. His scientific training includes significant expertise in basic research involving bacterial genetics/genomics, having spent many years investigating the molecular processes mediating bacterial iron transport and iron-controlled gene expression and the genomics of pathogenic mycoplasmas. More recent work has focused on the investigation of the role of iron-binding small molecules in the inflammatory response to adherent-invasive Escherichia coli (AIEC) in inflammatory bowel disease, and the linkage between iron-controlled virulence factors and the expression of two-partner contact-dependent inhibition (CDI) systems in the lung pathogenesis of Pseudomonas aeruginosa. In addition, Dr. McIntosh for close to 10 years directed a program-project grant in collaboration with USDA to develop new diagnostic and therapeutic targets for detection and control of foreign animal diseases, including mycoplasmas and pestiviruses. This project involved three primary laboratories at MU and collaborating laboratories at the Plum Island Animal Disease Center.

Over the course of his career, Dr. McIntosh has successfully garnered extramural support from NSF, NIH, USDA, Cystic Fibrosis Association of Missouri, the Missouri Life Sciences Research Board, as well as industry sponsors. Dr. McIntosh also serves a primary role in the development and operations of campus biotechnology core facilities, working to augment investigator-driven research in areas such as genomics, proteomics, metabolomics, structural biology and bioinformatics. Dr. McIntosh has served as the Director of the MU DNA Core Facility since 1987 and has seen it implement a constellation of genomics technologies over the years, including Sanger and Illumina next generation DNA sequencing platforms, gene expression technologies (including Affymetrix, Illumina Bead Station, Nimblegen and Illumina RNAseq), qPCR and RT-PCR technologies and high throughput DNA/RNA sample and library preparation. In 2004, Dr. McIntosh was appointed Director of the MU Core Facilities, with oversight responsibilities for seven additional campus technology centers for mass spectrometry, NMR spectroscopy, electron and light microscopy, flow cytometry, protein crystallization and x-ray diffraction, and transgenic animal production. His responsibilities include fiscal oversight, personnel staffing and technical development, and instrumentation and technology acquisition. In 2008, Dr. McIntosh and colleagues from around the campus were awarded a Life Sciences Trust Fund award from the State of Missouri to develop an Informatics Research Core Facility to enhance campus infrastructure and technical expertise in specific bioinformatics subdisciplines including genomics, proteomics and metabolomics.

In 2015, Dr. McIntosh was appointed Associate Vice Chancellor for Research and Strategic Initiatives. In this role, he worked with institutional research leaders to build programmatic initiatives that take advantage of strategic research and infrastructure resources in linkages to translational outcomes involving clinical and commercial applications. Key to these initiatives are the partnerships among the colleges of Engineering, Veterinary Medicine and Medicine in developing a robust Comparative Medicine/One Health approach to research investments.

In November 2015, he was appointed MU's Interim Vice Chancellor for Research and Economic Development. In June 2017, the MU position became permanent, and Dr. McIntosh was also appointed Vice President for Research and Economic Development for the four campus UM System, a position he held until 2019. As the administrator of research at MU, McIntosh is integral to the success of the chancellor’s challenge of doubling Mizzou’s research expenditures in the next five years. He also is spearheading the teams that are building the UM System’s number one capital priority, the NextGen Precision Health Institute, the multidisciplinary facility that will position the System and MU as a global leader in precision medicine, a revolutionary approach to disease treatment that delivers customized patient care based on an individual’s genes, environment and lifestyle.

Last Updated: January 9, 2020